Welcome to our dedicated page for Xilio Therapeutics news (Ticker: XLO), a resource for investors and traders seeking the latest updates and insights on Xilio Therapeutics stock.
Xilio Therapeutics, Inc. (Nasdaq: XLO) is a clinical-stage biotechnology company developing tumor-activated, or masked, immuno-oncology therapies for people living with cancer. The XLO news feed on Stock Titan aggregates company-issued press releases and related coverage so readers can follow how Xilio’s pipeline, collaborations and financial position evolve over time.
News about Xilio frequently centers on clinical and preclinical data from its key programs. These include vilastobart, an investigational tumor-activated, Fc-enhanced anti-CTLA-4 antibody being studied in combination with atezolizumab in advanced solid tumors and microsatellite stable metastatic colorectal cancer, and efarindodekin alfa (XTX301), a tumor-activated IL-12 in a Phase 1/2 trial for advanced solid tumors. The company also reports on progress for XTX501, a bispecific PD-1 / masked IL-2 molecule in IND-enabling studies, and multiple masked T cell engager programs targeting tumor-associated antigens such as PSMA, CLDN18.2 and STEAP1.
Investors can use this page to track Xilio’s announcements about clinical trial milestones, data presentations at scientific meetings like the Society for Immunotherapy of Cancer (SITC) and the American Society of Clinical Oncology (ASCO), and updates on collaborations with partners including Gilead, Roche and AbbVie. The feed also captures corporate developments such as financings, warrant exercises, cash runway guidance, stock option plans and board or leadership changes disclosed in press releases and related SEC filings.
By reviewing the XLO news stream, readers gain a consolidated view of how Xilio’s masked immunotherapy platform is progressing through research and development, how external partners are engaging with its programs, and how the company is addressing Nasdaq listing requirements and capital needs as it advances its oncology pipeline.
Xilio Therapeutics (Nasdaq: XLO) said company management will participate in a fireside chat at the Leerink Partners Global Healthcare Conference on March 9, 2026 at 3:00 p.m. ET.
A live webcast will be available at the company investor site ir.xiliotx.com, with a replay archived for 30 days after the presentation.
Xilio Therapeutics (Nasdaq: XLO) granted non-qualified stock options to two new employees effective March 1, 2026 under its 2022 Inducement Stock Incentive Plan. The awards total 50,050 options with an exercise price of $0.5283 per share, equal to the February 27, 2026 closing price.
Each option has a ten-year term and vests 25% after one year, with the remaining 75% vesting in 36 equal monthly installments, subject to continued service and plan terms.
Xilio Therapeutics (Nasdaq: XLO) priced an underwritten offering of 74,780,300 pre-funded warrants at $0.5349 each, exercisable for one share at $0.0001 per share. Gross proceeds are expected to be approximately $40.0 million, with closing on or about February 13, 2026, subject to customary conditions.
Investors include Coastlands Capital (lead), Gilead Sciences, OrbiMed, Perceptive Advisors and others. Leerink Partners is sole bookrunner. Net proceeds will be used to advance product development, working capital and general corporate purposes.
Xilio Therapeutics (NASDAQ: XLO) reported $35.8 million in gross proceeds from Series B warrant exercises and estimates $137.5 million in cash and cash equivalents as of December 31, 2025. The company said this funding extends its anticipated cash runway into the second quarter of 2027. Recent program updates include a development milestone for a masked antibody program under the AbbVie collaboration and nomination of a development candidate for a wholly owned masked T cell engager targeting CLDN18.2. Corporate changes include the appointment of Sara Bonstein as chair of the board. Anticipated next milestones include an IND submission for XTX501 in mid-2026 and initial Phase 1 data for XTX501 in H2 2027, subject to FDA clearance.
Xilio Therapeutics (Nasdaq: XLO) reported clinical and financial updates on Nov 13, 2025. At SITC, Phase 2 vilastobart data showed a 40% ORR in heavily pretreated, plasma TMB-high (≥10 mut/Mb) MSS mCRC patients without liver metastases, with p=0.05 correlation between plasma TMB and response. Phase 1 efarindodekin alfa monotherapy data showed promising anti-tumor activity and tolerability; XTX501 (bispecific PD-1/masked IL-2) is advancing toward a planned IND in mid-2026. Xilio presented preclinical masked T cell engager data and nominated a PSMA development candidate. Financials: $103.8M cash as of Sept 30, 2025; Q3 collaboration revenue $19.1M; net loss $16.3M. Company expects runway into Q1 2027.
Xilio Therapeutics (NASDAQ: XLO) reported late-breaking Phase 2 data for vilastobart plus atezolizumab at SITC on Nov 7, 2025 showing a 40% objective response rate (ORR) in heavily pre-treated patients with MSS metastatic colorectal cancer (mCRC) who had no liver metastases and high plasma TMB (≥10 mut/Mb).
Data cutoff was May 12, 2025: 44 patients treated (100 mg Q6W vilastobart + 1200 mg Q3W atezolizumab), 27 without liver metastases, 24 evaluable for plasma TMB. Company estimates ~55% of non‑MSI‑H CRC are plasma TMB‑high. Responses included tumor reductions up to 71%. Safety: mostly Grade 1–2, 5% discontinued for treatment‑related AEs and 7% experienced colitis. Xilio will host a conference call/webcast on Nov 10, 2025 at 4:30 p.m. ET.
Xilio Therapeutics (NASDAQ: XLO) presented preclinical and clinical data at SITC 2025 highlighting its masked immunotherapy platform and clinical-stage programs efarindodekin alfa (tumor-activated IL-12) and vilastobart (tumor-activated, Fc-enhanced anti-CTLA-4).
Key clinical facts: as of Sept 2, 2025 62 patients received efarindodekin alfa in Phase 1 dose escalation; doses exceeded recombinant IL-12 by >100-fold; two partial responses observed (confirmed PR: 33% reduction; unconfirmed PR: 55% reduction). Vilastobart Phase 2 ctDNA data (cutoff May 12, 2025) showed ≥75% ctDNA reductions correlated with radiographic response in 23 evaluable MSS mCRC patients without liver metastases.
Xilio Therapeutics (Nasdaq: XLO) granted a non-qualified stock option to purchase 5,700 shares to a new employee effective November 1, 2025, under its 2022 Inducement Stock Incentive Plan. The exercise price is $0.7967 per share, equal to the closing price on October 31, 2025. Each option has a 10-year term.
Vesting: 25% vests on the first anniversary of employment, with the remaining 75% vesting in 36 equal monthly installments thereafter, subject to continued service and plan/option agreement terms. The grant was made under Nasdaq Listing Rule 5635(c)(4).
Xilio Therapeutics (Nasdaq: XLO) will present late-breaking Phase 2 data for vilastobart (tumor-activated, Fc-enhanced anti-CTLA-4) at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting, Nov 5–9, 2025, National Harbor, Maryland.
The poster (Late-Breaking Abstract No. 1315) reports response rates for vilastobart combined with atezolizumab in patients with microsatellite stable (MSS) metastatic colorectal cancer enriched for high plasma tumor mutational burden (pTMB). Presentation: Friday, Nov 7, 2025; Poster Hall hours 9:00 a.m.–7:00 p.m. EST; Prince George ABC Exhibit Halls, Gaylord National Resort.
The poster will be posted on Nov 7, 2025 in the company’s "Our Approach—Presentations & Publications" section at www.xiliotx.com.
Xilio Therapeutics (Nasdaq: XLO) announced multiple poster presentations at the SITC 40th Annual Meeting, Nov 6-9, 2025, Gaylord National Convention Center, National Harbor, MD.
Xilio will present clinical data for vilastobart (anti-CTLA-4) and XTX301 (efarindodekin alfa) (tumor-activated IL-12), plus preclinical data on masked T cell engager programs. Key posters: ctDNA as a surrogate biomarker for vilastobart + atezolizumab in MSS mCRC (Abstract 541) and XTX301 Phase 1 IL-12 pharmacodynamic data (Abstract 567) — both presented Friday, Nov 7, 2025, poster hall 9:00 a.m.–7:00 p.m. EST (Gaylord Exhibit Halls A & B1). Masked T cell engager poster (Abstract 972) presented Saturday, Nov 8, 2025, poster hall 9:00 a.m.–8:40 p.m. EST.